Liu Hong-xia, Xing Ling-xiao, Wang Hong-bin, Yang Jun-quan, Sun Yu-man
Department of Pathology, Tangshan Xiehe Hospital, Tangshan 063000, China.
Zhonghua Bing Li Xue Za Zhi. 2008 Sep;37(9):615-9.
To study the relationship between expression of caveolin-1 (Cav-1) and pERK1/2 and prognosis in non-small cell lung cancer (NSCLC).
Cav-1 and pERK1/2 protein expression was assessed by immunohistochemistry in samples obtained from 160 patients with NSCLC and 20 patients with normal lung tissue.
Normal bronchial and alveolar epithelial cells were positive for Cav-1 (membranous and cytoplasmic staining patterns). The expression rate of Cav-1 in NSCLC was 65.6% (105/160), which was significantly lower than that in normal lung tissue (P = 0.002). The Cav-1-positive rates in well to moderately differentiated tumors and poorly differentiated tumors were 56.8% (46/81) and 75.7% (53/70), respectively (P = 0.015). The expression of Cav-1 was much higher in patients with lymph node metastasis (77.8%, compared with 55.7% in lymph node-negative group, P = 0.003). The expression was also higher in stage III to IV than in stage I to II disease (75.4%, compared with 58.2%, P = 0.024). The overall survival of patients with Cav-1-positive tumors (71.4%, 37.1% and 17.1% 1-, 3- and 5-year survival, respectively) was lower than those with Cav-1-negative tumors (89.1%, 69.1% and 43.6% 1-, 3- and 5-year survival, respectively, P = 0.000). On the other hand, normal bronchial and alveolar epithelial cells were negative for pERK1/2. The expression rate of pERK1/2 in NSCLC was 61.3%, which was significantly higher than that in normal lung tissues (P = 0.000). The pERK1/2-positive rates in well to moderately differentiated tumors and poorly differentiated tumors was 53.1% and 71.4%, respectively (P = 0.021). The expression of pERK1/2 was much higher in patients with lymph node metastasis (80.6%, compared with 45.5% in lymph node-negative group, P = 0.000). The expression of pERK1/2 was also higher in stage III to IV than in stage I to II disease (76.8%, compared with 49.5%, P = 0.426). The overall survival of patients with pERK1/2-positive tumors (74.5%, 42.9% and 19.4% 1-, 3- and 5-year survival, respectively) was lower than those with pERK1/2-negative tumors (82.3%, 56.5% and 37.1% 1-, 3- and 5-year survival, respectively, P = 0.002). Cav-1 and pERK1/2 expression showed negative correlation (P = 0.000).
Cav-1 expression is lower in NSCLC than in normal lung tissue, whereas pERK1/2 expression is higher in NSCLC. Positive expression of Cav-1 and overexpression of pERK1/2 correlates with tumorigenesis and tumor progression of NSCLC. Cav-1 and pERK1/2 may serve as potential markers for predicting prognosis in NSCLC.
研究小窝蛋白-1（Cav-1）和磷酸化细胞外信号调节激酶1/2（pERK1/2）的表达与非小细胞肺癌（NSCLC）预后的关系。
采用免疫组织化学法检测160例NSCLC患者及20例正常肺组织样本中Cav-1和pERK1/2蛋白的表达。
正常支气管和肺泡上皮细胞Cav-1呈阳性（膜性和胞质染色模式）。NSCLC中Cav-1的表达率为65.6%（105/160），显著低于正常肺组织（P = 0.002）。高分化至中分化肿瘤和低分化肿瘤中Cav-1的阳性率分别为56.8%（46/81）和75.7%（53/70）（P = 0.015）。有淋巴结转移患者中Cav-1的表达明显更高（77.8%，而淋巴结阴性组为55.7%，P = 0.003）。Ⅲ至Ⅳ期疾病中Cav-1的表达也高于Ⅰ至Ⅱ期（75.4%，而Ⅰ至Ⅱ期为58.2%，P = 0.024）。Cav-1阳性肿瘤患者的总生存率（1年、3年和5年生存率分别为71.4%、37.1%和17.1%）低于Cav-1阴性肿瘤患者（1年、3年和5年生存率分别为89.1%、69.1%和43.6%，P = 0.000）。另一方面，正常支气管和肺泡上皮细胞pERK1/2呈阴性。NSCLC中pERK1/2的表达率为61.3%，显著高于正常肺组织（P = 0.000）。高分化至中分化肿瘤和低分化肿瘤中pERK1/2的阳性率分别为53.1%和71.4%（P = 0.021）。有淋巴结转移患者中pERK1/2的表达明显更高（80.6%，而淋巴结阴性组为45.5%，P = 0.
